Sarawut Jitrapakdee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sarawut Jitrapakdee has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Siraprapa Siritutsoontorn
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand
7 shared publications- Paul V. Attwood
School of Molecular Sciences, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia
6 shared publications Chayanee Laowittawat
Mahidol University
5 shared publicationsPhatchariya Phannasil
Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon-Pathom, Thailand
5 shared publicationsJarunya Ngamkham
Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand
4 shared publications- Khanti Rattanapornsompong
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Riboflavin–Ceria Nanoparticles Induce ROS-Driven Mitochondrial Dysfunction in Breast Cancer
Cerium oxide nanoparticles (CeO2 NPs) are redox-active nanomaterials with emerging potential in cancer therapy, although their limited cytotoxicity and insufficient mechanistic understanding hinder clinical application. Here, we developed riboflavin-functionalized CeO2 nanoparticles (Rf-CeO2) to enhance photodynamic anticancer efficacy via controlled reactive oxygen species (ROS) generation and mitochondrial targeting. Rf conjugation improves nanoparticle stability and enables photodynamic activation under UV irradiation leading to elevated intracellular oxidative stress. In MDA-MB-231 breast cancer cells, Rf-CeO2 exhibits significantly enhanced cytotoxicity compared to pristine CeO2, inducing dose-dependent cell death and apoptosis. This effect is markedly potentiated by UV exposure, consistent with increased ROS-mediated oxidative stress. Proteomic analysis identifies 60 differentially expressed proteins, revealing disruptions of metabolic pathways, protein synthesis, and DNA repair. Notably, citrate synthase (CS), a key enzyme in the tricarboxylic acid cycle, is significantly downregulated and associated with poor prognosis in breast cancer. Functional validation using Seahorse Mito Stress and TMRM assays confirms mitochondrial dysfunction, including impaired oxidative phosphorylation, reduced ATP production, and loss of membrane potential. Overall, these results demonstrate that Rf-CeO2 acts as an effective photodynamic nanoplatform that induces cancer cell death through synergistic ROS generation and mitochondrial metabolic disruption. This study provides new proteomic insights into ceria-based nanotherapeutics and highlights citrate synthase as a potential therapeutic target for breast cancer.
- 9 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Open AccessRiboflavin–Ceria Nanoparticles Induce ROS-Driven Mitochondrial Dysfunction in Breast Cancer
Cerium oxide nanoparticles (CeO2 NPs) are redox-active nanomaterials with emerging potential in cancer therapy, although their limited cytotoxicity and insufficient mechanistic understanding hinder clinical application. Here, we developed riboflavin-functionalized CeO2 nanoparticles (Rf-CeO2) to enhance photodynamic anticancer efficacy via controlled reactive oxygen species (ROS) generation and mitochondrial targeting. Rf conjugation improves nanoparticle stability and enables photodynamic activation under UV irradiation leading to elevated intracellular oxidative stress. In MDA-MB-231 breast cancer cells, Rf-CeO2 exhibits significantly enhanced cytotoxicity compared to pristine CeO2, inducing dose-dependent cell death and apoptosis. This effect is markedly potentiated by UV exposure, consistent with increased ROS-mediated oxidative stress. Proteomic analysis identifies 60 differentially expressed proteins, revealing disruptions of metabolic pathways, protein synthesis, and DNA repair. Notably, citrate synthase (CS), a key enzyme in the tricarboxylic acid cycle, is significantly downregulated and associated with poor prognosis in breast cancer. Functional validation using Seahorse Mito Stress and TMRM assays confirms mitochondrial dysfunction, including impaired oxidative phosphorylation, reduced ATP production, and loss of membrane potential. Overall, these results demonstrate that Rf-CeO2 acts as an effective photodynamic nanoplatform that induces cancer cell death through synergistic ROS generation and mitochondrial metabolic disruption. This study provides new proteomic insights into ceria-based nanotherapeutics and highlights citrate synthase as a potential therapeutic target for breast cancer.
- Open Access
- 13 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (29) , 44169-44182
Potent Anti-adipogenic Activity of Cyclopeptide Mallotumide A on Murine 3T3-L1 Adipocytes
Mallotumide A, a cyclic heptapeptide from Mallotus spodocarpus previously noted for its anti-lipogenic properties in cancer models, was evaluated for its effect on 3T3-L1 adipogenesis. Cytotoxicity assays (24–48 h exposure) established an IC50 value of approximately 1 nM in preadipocytes. Notably, mature adipocytes maintained nearly 100% viability at concentrations from 0.001 to 1 nM, defining a nontoxic range to investigate the compound’s modulation of lipid metabolism and differentiation. Treatment of preadipocytes with 1 nM Mallotumide A throughout the 10 day adipogenic differentiation process inhibited maturation into late-stage adipocytes and abolished lipid droplet accumulation. This effect was driven by the sustained downregulation of the master adipogenic regulators C/EBPα and PPARγ across both the early and late stages of differentiation. The disruption of these core transcriptional drivers subsequently reduced the expression of lipogenic enzymes, including pyruvate carboxylase, acetyl-CoA carboxylase 1, and fatty acid synthase, thereby preventing the maturation of the adipocytes. Mallotumide A also impaired growth signaling by reducing Akt protein. In contrast, stress-activated kinases, including JNK and p38, were not affected. The impaired differentiation was not attributed to apoptosis induction, as neither caspase-3 protein level nor caspase-3/7 activity was altered. The analysis of oxygen consumption profiles revealed that Mallotumide A did not significantly impair major mitochondrial bioenergetic parameters. However, in immature adipocytes, Mallotumide A moderately reduced mitochondrial spare respiratory capacity while maintaining normal basal and ATP-linked respiration. Collectively, these findings indicate that Mallotumide A predominantly targets both the early and late stages of differentiation. This effect is mediated through the downregulation of key adipogenic regulators and lipogenic enzymes, alongside the partial modulation of mitochondrial metabolism.
- 13 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (29) , 44169-44182
Open AccessPotent Anti-adipogenic Activity of Cyclopeptide Mallotumide A on Murine 3T3-L1 Adipocytes
Mallotumide A, a cyclic heptapeptide from Mallotus spodocarpus previously noted for its anti-lipogenic properties in cancer models, was evaluated for its effect on 3T3-L1 adipogenesis. Cytotoxicity assays (24–48 h exposure) established an IC50 value of approximately 1 nM in preadipocytes. Notably, mature adipocytes maintained nearly 100% viability at concentrations from 0.001 to 1 nM, defining a nontoxic range to investigate the compound’s modulation of lipid metabolism and differentiation. Treatment of preadipocytes with 1 nM Mallotumide A throughout the 10 day adipogenic differentiation process inhibited maturation into late-stage adipocytes and abolished lipid droplet accumulation. This effect was driven by the sustained downregulation of the master adipogenic regulators C/EBPα and PPARγ across both the early and late stages of differentiation. The disruption of these core transcriptional drivers subsequently reduced the expression of lipogenic enzymes, including pyruvate carboxylase, acetyl-CoA carboxylase 1, and fatty acid synthase, thereby preventing the maturation of the adipocytes. Mallotumide A also impaired growth signaling by reducing Akt protein. In contrast, stress-activated kinases, including JNK and p38, were not affected. The impaired differentiation was not attributed to apoptosis induction, as neither caspase-3 protein level nor caspase-3/7 activity was altered. The analysis of oxygen consumption profiles revealed that Mallotumide A did not significantly impair major mitochondrial bioenergetic parameters. However, in immature adipocytes, Mallotumide A moderately reduced mitochondrial spare respiratory capacity while maintaining normal basal and ATP-linked respiration. Collectively, these findings indicate that Mallotumide A predominantly targets both the early and late stages of differentiation. This effect is mediated through the downregulation of key adipogenic regulators and lipogenic enzymes, alongside the partial modulation of mitochondrial metabolism.
- Open Access
- 20 January 2026
- Published by Wiley in Macromolecular Materials and Engineering
- Vol. 311 (1)
Encapsulation of Plant‐Derived Cycloheptapeptide Mallotumide A in Riboflavin‐Modified Poly(Lactic‐Co‐Glycolic Acid)/Chitosan Nanoparticles
Mallotumide A (MA) is a novel cycloheptapeptide isolated from the roots of Mallotus spodocarpus Airy Shaw. It exerts anticancer activity by downregulating several lipogenic enzymes and cellular respiration, particularly in triple‐negative breast cancer. However, MA has poor water solubility and is highly toxic to both cancer and normal cells, limiting its therapeutic applications. To address these drawbacks, MA was encapsulated within poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles (NPs) and coated with riboflavin (Rf)‐modified chitosan (CR), creating (MA)PLGA/CR NPs. This study characterized the NPs and investigated their encapsulation efficiency of MA, cellular uptake, and anticancer activity in two breast cancer (MDA‐MB‐231 and MCF‐7) and normal (MCF‐10A) cell lines. The NPs were spherical with an average size of 300 ± 6.64 nm and a zeta potential of +11.96 mV. The PLGA/CR NPs exhibited enhanced cellular uptake in both cancer cells in a dose‐ and time‐dependent manner, while reducing toxicity in normal cells. Furthermore, the (MA)PLGA/CR NPs inhibited the viability, migration, and invasion of MDA‐MB‐231 cells, thereby demonstrating their potential as a targeted anticancer delivery system.
- 20 January 2026
- Published by Wiley in Macromolecular Materials and Engineering
- Vol. 311 (1)
Open AccessEncapsulation of Plant‐Derived Cycloheptapeptide Mallotumide A in Riboflavin‐Modified Poly(Lactic‐Co‐Glycolic Acid)/Chitosan Nanoparticles
Mallotumide A (MA) is a novel cycloheptapeptide isolated from the roots of Mallotus spodocarpus Airy Shaw. It exerts anticancer activity by downregulating several lipogenic enzymes and cellular respiration, particularly in triple‐negative breast cancer. However, MA has poor water solubility and is highly toxic to both cancer and normal cells, limiting its therapeutic applications. To address these drawbacks, MA was encapsulated within poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles (NPs) and coated with riboflavin (Rf)‐modified chitosan (CR), creating (MA)PLGA/CR NPs. This study characterized the NPs and investigated their encapsulation efficiency of MA, cellular uptake, and anticancer activity in two breast cancer (MDA‐MB‐231 and MCF‐7) and normal (MCF‐10A) cell lines. The NPs were spherical with an average size of 300 ± 6.64 nm and a zeta potential of +11.96 mV. The PLGA/CR NPs exhibited enhanced cellular uptake in both cancer cells in a dose‐ and time‐dependent manner, while reducing toxicity in normal cells. Furthermore, the (MA)PLGA/CR NPs inhibited the viability, migration, and invasion of MDA‐MB‐231 cells, thereby demonstrating their potential as a targeted anticancer delivery system.
- Open Access
- 30 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Riboflavin-PLGA nanoparticles enhance the effectiveness of the pyruvate carboxylase inhibitor ZY-444 in targeting lipogenesis in colon and breast cancer
Targeting cancer metabolism has become a promising strategy for cancer treatment. Pyruvate carboxylase (PC) is an anaplerotic enzyme that replenishes tricarboxylic acid cycle intermediates. PC is overexpressed in several types of human cancers, especially in aggressive cancers, including breast and colon cancer, where it promotes growth, survival, and metastasis. Recently, N4-((5-(4-(benzyloxy)phenyl)-2-thiophenyl)methyl)-N2-isobutyl-2,4-pyrimidinediamine (ZY-444) has been reported to possess anti-cancer activity by inhibiting PC activity in breast cancer. In this study, we expanded the potential of ZY-444 to highly aggressive colon cancer, HT-29 and HCT116, and further enhanced its efficacy using nanodelivery systems. The results reveal that ZY-444 not only inhibits the clonogenic growth of these colon cancer cells but also downregulates the expression of several key lipogenic enzymes, accompanied by a marked reduction in triglyceride and cholesterol levels. To improve its efficacy, ZY-444 was encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles with a surface coated with riboflavin (Rf)-functionalized chitosan (CSRf), a ligand known to target Rf transporters. The ZY-444-loaded PLGA nanoparticles exhibited a spherical morphology with an approximate size of 300 nm and a positive zeta potential, demonstrating their suitability for drug delivery applications. Compared with the free compound, ZY-444 encapsulated in nanoparticles demonstrated markedly enhanced efficacy being 11-, 14-, and 19-fold more potent in inhibiting the clonogenic growth of HT-29, HCT116, and MDA-MB-231 cells, respectively. In addition, the encapsulated form was over 10 times more effective at suppressing the migration and invasion of HCT116 and MDA-MB-231 cells. Encapsulated ZY-444 also more strongly inhibited the expression of lipogenic enzymes, further reinforcing its effect on lipid metabolism. Collectively, these findings underscore the potential of ZY-444-loaded PLGA nanoparticles as a promising drug delivery system for suppressing colon and breast cancer through targeted inhibition of the de novo lipogenesis pathway.
- 30 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessRiboflavin-PLGA nanoparticles enhance the effectiveness of the pyruvate carboxylase inhibitor ZY-444 in targeting lipogenesis in colon and breast cancer
Targeting cancer metabolism has become a promising strategy for cancer treatment. Pyruvate carboxylase (PC) is an anaplerotic enzyme that replenishes tricarboxylic acid cycle intermediates. PC is overexpressed in several types of human cancers, especially in aggressive cancers, including breast and colon cancer, where it promotes growth, survival, and metastasis. Recently, N4-((5-(4-(benzyloxy)phenyl)-2-thiophenyl)methyl)-N2-isobutyl-2,4-pyrimidinediamine (ZY-444) has been reported to possess anti-cancer activity by inhibiting PC activity in breast cancer. In this study, we expanded the potential of ZY-444 to highly aggressive colon cancer, HT-29 and HCT116, and further enhanced its efficacy using nanodelivery systems. The results reveal that ZY-444 not only inhibits the clonogenic growth of these colon cancer cells but also downregulates the expression of several key lipogenic enzymes, accompanied by a marked reduction in triglyceride and cholesterol levels. To improve its efficacy, ZY-444 was encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles with a surface coated with riboflavin (Rf)-functionalized chitosan (CSRf), a ligand known to target Rf transporters. The ZY-444-loaded PLGA nanoparticles exhibited a spherical morphology with an approximate size of 300 nm and a positive zeta potential, demonstrating their suitability for drug delivery applications. Compared with the free compound, ZY-444 encapsulated in nanoparticles demonstrated markedly enhanced efficacy being 11-, 14-, and 19-fold more potent in inhibiting the clonogenic growth of HT-29, HCT116, and MDA-MB-231 cells, respectively. In addition, the encapsulated form was over 10 times more effective at suppressing the migration and invasion of HCT116 and MDA-MB-231 cells. Encapsulated ZY-444 also more strongly inhibited the expression of lipogenic enzymes, further reinforcing its effect on lipid metabolism. Collectively, these findings underscore the potential of ZY-444-loaded PLGA nanoparticles as a promising drug delivery system for suppressing colon and breast cancer through targeted inhibition of the de novo lipogenesis pathway.
- Open Access
- 19 December 2025
- Published by Taylor & Francis in Adipocyte
- Vol. 15 (1) , 2601405
Erianin inhibits 3T3-L1 adipocyte differentiation through downregulation of CCAAT-enhancer binding protein-α and peroxisome proliferator-activated receptor-γ, lipogenic genes and impairment of mitochondrial respiration
Erianin, a natural bibenzyl compound, has recently garnered attention owing to its diverse biological activities. In the present study, we investigated the effects of Erianin on adipocyte differentiation, lipid metabolism, and mitochondrial respiration in murine 3T3-L1 cells. Cytotoxicity assays indicated that Erianin exhibited low toxicity towards preadipocytes at concentrations up to 200 μM. Treatment with 20 μM Erianin completely inhibited the differentiation of 3T3-L1 preadipocytes into mature adipocytes and reduced lipid droplets. Western blot analysis revealed that Erianin attenuated Akt and p38 MAPK signalling without inducing apoptosis, suppressed the expression of key pro-adipogenic transcription factors, C/EBPα and PPARγ during the early stages of differentiation. This suppression was accompanied by the downregulation of lipogenic enzymes, including acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), pyruvate carboxylase (PC) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). While early-stage differentiation was robustly inhibited, higher concentrations (≥25 μM) were required to suppress terminal differentiation of immature adipocytes. This late-stage inhibition was accompanied by decreased expression of PPARγ, PC, and HMGCR, with minimal effects on ACC1 and FASN, suggesting a more modest role for Erianin in terminal adipogenesis. Assessment of mitochondrial metabolism of 3T3-L1 cells following 24-hour treatment of Erianin showed that it modestly impaired ATP-linked respiration, maximal respiration, spare respiratory capacity and intracellular ATP levels while basal respiration was unaffected. Collectively, these findings indicated that Erianin predominantly targets early adipogenic differentiation and mitochondrial bioenergetics.
- 19 December 2025
- Published by Taylor & Francis in Adipocyte
- Vol. 15 (1) , 2601405
Open AccessErianin inhibits 3T3-L1 adipocyte differentiation through downregulation of CCAAT-enhancer binding protein-α and peroxisome proliferator-activated receptor-γ, lipogenic genes and impairment of mitochondrial respiration
Erianin, a natural bibenzyl compound, has recently garnered attention owing to its diverse biological activities. In the present study, we investigated the effects of Erianin on adipocyte differentiation, lipid metabolism, and mitochondrial respiration in murine 3T3-L1 cells. Cytotoxicity assays indicated that Erianin exhibited low toxicity towards preadipocytes at concentrations up to 200 μM. Treatment with 20 μM Erianin completely inhibited the differentiation of 3T3-L1 preadipocytes into mature adipocytes and reduced lipid droplets. Western blot analysis revealed that Erianin attenuated Akt and p38 MAPK signalling without inducing apoptosis, suppressed the expression of key pro-adipogenic transcription factors, C/EBPα and PPARγ during the early stages of differentiation. This suppression was accompanied by the downregulation of lipogenic enzymes, including acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), pyruvate carboxylase (PC) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). While early-stage differentiation was robustly inhibited, higher concentrations (≥25 μM) were required to suppress terminal differentiation of immature adipocytes. This late-stage inhibition was accompanied by decreased expression of PPARγ, PC, and HMGCR, with minimal effects on ACC1 and FASN, suggesting a more modest role for Erianin in terminal adipogenesis. Assessment of mitochondrial metabolism of 3T3-L1 cells following 24-hour treatment of Erianin showed that it modestly impaired ATP-linked respiration, maximal respiration, spare respiratory capacity and intracellular ATP levels while basal respiration was unaffected. Collectively, these findings indicated that Erianin predominantly targets early adipogenic differentiation and mitochondrial bioenergetics.
- Open Access
- 19 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40774
The cyclic peptide mallotumide A inhibits colon and breast cancer cell growth and motility by targeting cellular respiration and lipogenesis
We have recently isolated, and determined the structure of a cycloheptapeptide, Mallotumide A from the Mallotus spodocarpus root extract. Here we reported the anti-cancer activity of Mallotumide A in highly invasive colon cancer, HCT116 and triple-negative breast cancer, MDA-MB-231 cell lines. Mallotumide A, at concentrations of 1 nM and 10 nM, completely inhibited the clonogenic growth, migration, and invasion of HCT116 and MDA-MB-231 cells, respectively. While the compound interfered with cell cycle progression without inducing apoptosis, exposure to 10 nM Mallotumide A for 48 h reduced the expression of two key lipogenic enzymes, ACC1 and FASN, by approximately 50% in both cell lines. The downregulation of ACC1 and FASN was accompanied by a 50% reduction in intracellular triglyceride levels while the cholesterol levels remained unaffected. Mallotumide A also moderately decreased AMP-activated protein kinase (AMPK) and ATP levels. Extracellular flux analysis revealed that acute exposure of both cancer cell lines to 1 nM and 10 nM Mallotumide A for 24 h markedly lowered the oxygen consumption rate. This was accompanied by reductions in basal and ATP-linked respiration, maximal respiration, and mitochondrial spare respiratory capacity. Mallotumide A also decreased the extracellular acidification rate, affecting both basal glycolysis and the glycolytic reserve. These findings suggest that the anti-cancer effects of Mallotumide A are associated with disruptions in cellular energy metabolism and the de novo lipogenesis pathway in cancer cells. This study underscores the potential of Mallotumide A as a novel anti-cancer agent.
- 19 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40774
Open AccessThe cyclic peptide mallotumide A inhibits colon and breast cancer cell growth and motility by targeting cellular respiration and lipogenesis
We have recently isolated, and determined the structure of a cycloheptapeptide, Mallotumide A from the Mallotus spodocarpus root extract. Here we reported the anti-cancer activity of Mallotumide A in highly invasive colon cancer, HCT116 and triple-negative breast cancer, MDA-MB-231 cell lines. Mallotumide A, at concentrations of 1 nM and 10 nM, completely inhibited the clonogenic growth, migration, and invasion of HCT116 and MDA-MB-231 cells, respectively. While the compound interfered with cell cycle progression without inducing apoptosis, exposure to 10 nM Mallotumide A for 48 h reduced the expression of two key lipogenic enzymes, ACC1 and FASN, by approximately 50% in both cell lines. The downregulation of ACC1 and FASN was accompanied by a 50% reduction in intracellular triglyceride levels while the cholesterol levels remained unaffected. Mallotumide A also moderately decreased AMP-activated protein kinase (AMPK) and ATP levels. Extracellular flux analysis revealed that acute exposure of both cancer cell lines to 1 nM and 10 nM Mallotumide A for 24 h markedly lowered the oxygen consumption rate. This was accompanied by reductions in basal and ATP-linked respiration, maximal respiration, and mitochondrial spare respiratory capacity. Mallotumide A also decreased the extracellular acidification rate, affecting both basal glycolysis and the glycolytic reserve. These findings suggest that the anti-cancer effects of Mallotumide A are associated with disruptions in cellular energy metabolism and the de novo lipogenesis pathway in cancer cells. This study underscores the potential of Mallotumide A as a novel anti-cancer agent.
- Open Access
- 22 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10170
Augmented Global Protein Acetylation Diminishes Cell Growth and Migration of Cholangiocarcinoma Cells
We have previously shown that the overexpression of acetyl-CoA carboxylase 1 (ACC1) was associated with the poor prognosis of cholangiocarcinoma (CCA) patients, and suppression of its expression in CCA cell lines deteriorated cell growth. The present study explored the mechanism by which ACC1 inhibition affects global protein acetylation, using genetic knockdown and pharmacological inhibition with an ACC1 inhibitor ND-646 as models. Both ACC1 knockdown and ACC1-inhibitor-treated cells displayed the hyperacetylation of proteins, accompanied by impaired growth and migration. The immunoprecipitation of hyperacetylated proteins using the anti-acetylated lysine antibody, followed by tandem mass spectrometry, identified three potential verification candidates, namely POTE ankyrin domain family member E, peroxisomal biogenesis factor 1, and heat shock protein 90 beta (HSP90B). HSP90 acetylation was the candidate selected for the verification of protein acetylation. To establish the effects of protein hyperacetylation, treatment with suberoylanilide hydroxamic acid (SAHA), a lysine deacetylase inhibitor, was conducted, and this served as an independent model. Decreased tumor growth but increased acetylated protein levels were observed in ACC1-KD xenograft tumors. Hyperacetylated-alleviated cell growth and migration were consistently observed in the SAHA-treated models. The molecular linkage between protein hyperacetylation and the AKT/GSK3β/Snail pathway was demonstrated. This study highlighted the importance of protein acetylation in CCA progression, suggesting that ACC1 and KDAC are potential targets for CCA treatment.
- 22 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10170
Open AccessAugmented Global Protein Acetylation Diminishes Cell Growth and Migration of Cholangiocarcinoma Cells
We have previously shown that the overexpression of acetyl-CoA carboxylase 1 (ACC1) was associated with the poor prognosis of cholangiocarcinoma (CCA) patients, and suppression of its expression in CCA cell lines deteriorated cell growth. The present study explored the mechanism by which ACC1 inhibition affects global protein acetylation, using genetic knockdown and pharmacological inhibition with an ACC1 inhibitor ND-646 as models. Both ACC1 knockdown and ACC1-inhibitor-treated cells displayed the hyperacetylation of proteins, accompanied by impaired growth and migration. The immunoprecipitation of hyperacetylated proteins using the anti-acetylated lysine antibody, followed by tandem mass spectrometry, identified three potential verification candidates, namely POTE ankyrin domain family member E, peroxisomal biogenesis factor 1, and heat shock protein 90 beta (HSP90B). HSP90 acetylation was the candidate selected for the verification of protein acetylation. To establish the effects of protein hyperacetylation, treatment with suberoylanilide hydroxamic acid (SAHA), a lysine deacetylase inhibitor, was conducted, and this served as an independent model. Decreased tumor growth but increased acetylated protein levels were observed in ACC1-KD xenograft tumors. Hyperacetylated-alleviated cell growth and migration were consistently observed in the SAHA-treated models. The molecular linkage between protein hyperacetylation and the AKT/GSK3β/Snail pathway was demonstrated. This study highlighted the importance of protein acetylation in CCA progression, suggesting that ACC1 and KDAC are potential targets for CCA treatment.
- Open Access
- 11 January 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1250423
Proteomic analysis of holocarboxylase synthetase deficient-MDA-MB-231 breast cancer cells revealed the biochemical changes associated with cell death, impaired growth signaling, and metabolism
We have previously shown that the holocarboxylase synthetase (HLCS) is overexpressed in breast cancer tissue of patients, and silencing of its expression in triple-negative cancer cell line inhibits growth and migration. Here we investigated the global biochemical changes associated with HLCS knockdown in MDA-MB-231 cells to discern the pathways that involve HLCS. Proteomic analysis of two independent HLCS knockdown cell lines identified 347 differentially expressed proteins (DEPs) whose expression change > 2-fold (p < 0.05) relative to the control cell line. GO enrichment analysis showed that these DEPs were mainly associated with the cellular process such as cellular metabolic process, cellular response to stimulus, and cellular component organization or biogenesis, metabolic process, biological regulation, response to stimuli, localization, and signaling. Among the 347 identified DEPs, 64 proteins were commonly found in both HLCS knockdown clones, confirming their authenticity. Validation of some of these DEPs by Western blot analysis showed that plasminogen activator inhibitor type 2 (SerpinB2) and interstitial collagenase (MMP1) were approximately 90% decreased in HLCS knockdown cells, consistent with a 50%–60% decrease in invasion ability of knockdown cells. Notably, argininosuccinate synthase 1 (ASS1), one of the enzymes in the urea cycle, showed approximately a 10-fold increase in the knockdown cells, suggesting the crucial role of HLCS in supporting the urea cycle in the triple-negative cancer cell line. Collectively, our proteomic data provide biochemical insights into how suppression of HLCS expression perturbs global changes in cellular processes and metabolic pathways, impairing cell growth and invasion.
- 11 January 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1250423
Open AccessProteomic analysis of holocarboxylase synthetase deficient-MDA-MB-231 breast cancer cells revealed the biochemical changes associated with cell death, impaired growth signaling, and metabolism
We have previously shown that the holocarboxylase synthetase (HLCS) is overexpressed in breast cancer tissue of patients, and silencing of its expression in triple-negative cancer cell line inhibits growth and migration. Here we investigated the global biochemical changes associated with HLCS knockdown in MDA-MB-231 cells to discern the pathways that involve HLCS. Proteomic analysis of two independent HLCS knockdown cell lines identified 347 differentially expressed proteins (DEPs) whose expression change > 2-fold (p < 0.05) relative to the control cell line. GO enrichment analysis showed that these DEPs were mainly associated with the cellular process such as cellular metabolic process, cellular response to stimulus, and cellular component organization or biogenesis, metabolic process, biological regulation, response to stimuli, localization, and signaling. Among the 347 identified DEPs, 64 proteins were commonly found in both HLCS knockdown clones, confirming their authenticity. Validation of some of these DEPs by Western blot analysis showed that plasminogen activator inhibitor type 2 (SerpinB2) and interstitial collagenase (MMP1) were approximately 90% decreased in HLCS knockdown cells, consistent with a 50%–60% decrease in invasion ability of knockdown cells. Notably, argininosuccinate synthase 1 (ASS1), one of the enzymes in the urea cycle, showed approximately a 10-fold increase in the knockdown cells, suggesting the crucial role of HLCS in supporting the urea cycle in the triple-negative cancer cell line. Collectively, our proteomic data provide biochemical insights into how suppression of HLCS expression perturbs global changes in cellular processes and metabolic pathways, impairing cell growth and invasion.
- 23 September 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (1) , 166886
Corrigendum to “Diminishing acetyl-CoA carboxylase 1 attenuates CCA migration via AMPK-NF-κB-snail axis” [Biochim. Biophys. Acta Mol. Basis Dis. 1869 (5) (2023) 166694 (PMID: 36972768)]
- 23 September 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (1) , 166886
Corrigendum to “Diminishing acetyl-CoA carboxylase 1 attenuates CCA migration via AMPK-NF-κB-snail axis” [Biochim. Biophys. Acta Mol. Basis Dis. 1869 (5) (2023) 166694 (PMID: 36972768)]
- 25 March 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1869 (5) , 166694
Diminishing acetyl-CoA carboxylase 1 attenuates CCA migration via AMPK-NF-κB-snail axis
- 25 March 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1869 (5) , 166694
Diminishing acetyl-CoA carboxylase 1 attenuates CCA migration via AMPK-NF-κB-snail axis